Overcoming the limits of standard of care therapies
Starton is a clinical-stage biotechnology company transforming standard of care therapies with proprietary continuous delivery technology, so people with cancer can receive continuous treatment to live better, longer.
“Cancer touches all of us, directly and indirectly. Today, life is often extended for a short period, and for most people with cancer, quality of life deteriorates significantly. At Starton, we are developing an approach to provide people with cancer longer, high quality lives. We are eliminating or minimizing the horrible side effects they experience every day by unlocking the full potential of approved drugs.”
Pedro Lichtinger, Co-Founder, Chairman, & CEO